Loading your page…
Marketing-authorisation holder
4 medicines in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
4 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ZARELIS RETARD 150 MG COMPRIMIDOS DE LIBERACION PROLONGADA169,72 mg · Comprimido de liberación prolongada | Venlafaxine | Spain | Marketed | 2024 |
| ZARELIS RETARD 150 MG COMPRIMIDOS DE LIBERACION PROLONGADA169,72 mg · Comprimido de liberación prolongada | Venlafaxine | Spain | Marketed | 2025 |
| ZARELIS RETARD 75 MG COMPRIMIDOS DE LIBERACION PROLONGADA84,86 mg · Comprimido de liberación prolongada | Venlafaxine | Spain | Marketed | 2025 |
| ZARELIS RETARD 75 MG COMPRIMIDOS DE LIBERACION PROLONGADA84,86 mg · Comprimido de liberación prolongada | Venlafaxine | Spain | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 4 | 4 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Report an error or request removalCorrections from the company itself are welcome.
